Skip to content
Peptigraph home

Ecnoglutide: Trials and FDA Status

Ecnoglutide is a glp-1 agonist. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated

Where it stands

US status
Investigational
Phase
Phase 3
Sponsor
Hangzhou Sciwind Biosciences
Expected FDA decision
None announced
no primary source states a date (checked 2 Oct 2026)
Results

Reported results

  • 2025Phase 3 in Chinese adults with overweight or obesity (Lancet Diabetes Endocrinol 2025): weight change at week 40“At week 40, the least-squares mean percentage change in bodyweight was -9·1% (SE 0·8) in the ecnoglutide 1·2 mg group, -10·9% (0·9) in the ecnoglutide 1·8 mg group, and -13·2% (0·8) in the ecnoglutide 2·4 mg group versus 0·1% (0·8) in the placebo group”pubmed.ncbi.nlm.nih.gov
  • 2026Phase 3 in type 2 diabetes (2026): HbA1c change at week 24“At week 24, the least squares mean changes from baseline in HbA1c were -1.96% (95% CI -2.18 to -1.73) with ecnoglutide 0.6 mg and -2.43% (95% CI -2.65 to -2.20) with ecnoglutide 1.2 mg versus -0.87% (-1.09 to -0.65) with placebo.”pubmed.ncbi.nlm.nih.gov

Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.

Timeline

Milestones

  1. Published in Nature communications (2026): Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.
  2. Review in Drugs (2026) reports first approvals of ecnoglutide in China: type 2 diabetes (January 2026) and long-term weight management (March 2026)
  3. Published in The lancet. Diabetes & endocrinology (2025): Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
  4. Published in The lancet. Diabetes & endocrinology (2025): Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.
  5. NCT05680129 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM; Phase 3): primary completion
  6. NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity; Phase 3): primary completion
  7. NCT05680155 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients; Phase 3): primary completion
  8. Published in Nature communications (2024): Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.
  9. NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity; Phase 3): first posted on ClinicalTrials.gov
  10. NCT05813795 (A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity; Phase 3): study start
  11. NCT05680155 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients; Phase 3): first posted on ClinicalTrials.gov
  12. NCT05680129 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM; Phase 3): first posted on ClinicalTrials.gov
  13. NCT05680129 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM; Phase 3): study start
  14. NCT05680155 (A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients; Phase 3): study start
  15. NCT05111912 (Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity; Phase 2): primary completion
  16. NCT05111912 (Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity; Phase 2): study start
  17. NCT05111912 (Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity; Phase 2): first posted on ClinicalTrials.gov

What the ecnoglutide registry entries specify

SLIMMER (NCT05813795) is titled as a phase 3, randomised, double-blind, placebo-controlled study of XW003 in adults with overweight or obesity.[2]

SLIMMER enrolled 664 participants.[2]

SLIMMER is completed: it started 2023-04-05 and reached primary completion on 2024-06-20.[2]

The phase 2 trial against liraglutide enrolled 206 participants.[1]

In the open-label phase 2 study, ecnoglutide started at 0.2 mg and was up-titrated to 1.2, 1.8 or 2.4 mg once weekly, with daily liraglutide as the comparator.[1]

Primary endpoints and trial length

SLIMMER's first primary outcome is percent change in body weight from baseline at Week 40.[2]

Its second primary outcome is the proportion of participants losing at least 5% of baseline weight, also at Week 40.[2]

SLIMMER spans 63 weeks from start to primary completion.

Calculated from NCT05813795 start 2023-04-05, primary completion 2024-06-20, type ACTUAL. Formula: weeks = round((primary completion date - start date) / 7 days)

Published phase 3 results

In the phase 3 obesity trial in Chinese adults, weight changed by -9.1% at 1.2 mg, -10.9% at 1.8 mg and -13.2% at 2.4 mg at week 40, against 0.1% on placebo.[6]

In type 2 diabetes, HbA1c fell by 1.96% at 0.6 mg and 2.43% at 1.2 mg, against 0.87% on placebo at week 24.[8]

Approval in China

A 2026 review says ecnoglutide received its first approval in China in January 2026, for glycaemic control in adults with type 2 diabetes.[9]

Common questions

Is ecnoglutide in phase 3?

Yes. SLIMMER is a registered phase 3 trial in adults with overweight or obesity, and it has completed.[2]

Sources

  1. 1Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity (NCT05111912)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  2. 2A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity (NCT05813795)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  3. 3A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients (NCT05680155)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
  4. 4A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM (NCT05680129)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
  5. 5Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.Nature communications · 2024PMID 39333121Accessed 2 Oct 2026
  6. 6Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.The lancet. Diabetes & endocrinology · 2025PMID 40555243Accessed 2 Oct 2026
  7. 7Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.The lancet. Diabetes & endocrinology · 2025PMID 40854315Accessed 2 Oct 2026
  8. 8Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.Nature communications · 2026PMID 41501026Accessed 2 Oct 2026
  9. 9Ecnoglutide: First Approvals.Drugs · 2026PMID 42412371Accessed 2 Oct 2026

Found an error? Report a correction.